MEIP Dividend History & Description — MEI Pharma Inc
MEI Pharma is a clinical-stage pharmaceutical company focused on developing cancer therapies. Co.'s drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. When considering the MEI Pharma Inc stock dividend history, we have taken known splits into account, such that the MEIP dividend history is presented on a split-adjusted ("apples to apples") basis. MEI Pharma Inc dividend history is presented both in graphical/chart form, and as a MEIP dividend history data table along the right-hand column.
|
MEIP Stock Dividend HistoryThe MEIP dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable MEIP historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the MEIP dividend history record. Also see the MEIP stock dividend history data table along the right-hand column below. |
|
|
Buy (3.00 out of 4) 33rd percentile
(ranked lower than approx. 67% of all stocks covered)
Analysts' Target Price: MEIP Forecast Based on data provided by Zacks Investment Research via Quandl.com |